Protara Therapeutics Investor Relations Material
Latest events
Status Update
Protara Therapeutics
Q2 2025
11 Aug, 2025
Q1 2025
8 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Protara Therapeutics Inc
Access all reports
Protara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing transformative therapies for cancer and rare diseases. Their lead program, TARA-002, is an investigational cell therapy aimed at treating lymphatic malformations, based on the broad immunopotentiator OK-432. Additionally, Protara is developing intravenous choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. The company is headquartered in NYC, and its shares are listed on the Nasdaq.
Key slides for Protara Therapeutics Inc
43rd Annual J.P. Morgan Healthcare Conference 2025
Protara Therapeutics Inc
43rd Annual J.P. Morgan Healthcare Conference 2025
Protara Therapeutics Inc
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
TARA
Country
🇺🇸 United States